Editorial Staff

Assistant Editor

Prof.. Muhammad Asif Qureshi

Tumor Immunology Department of Pathology, Dow International Medical College, Dow University of Health Sciences (OJHA CAMPUS), Karachi, Pakistan

asif@asifqureshi.com
+923002185053


Dr. Asif is a Clinician Scientist with special interests in the field of Tumour Immunology. After completing his medical training, he completed the degree of Ph.D. at the University of Glasgow, UK in the field of viral-associated carcinogenesis. Dr. Asif also achieved the Humboldt Fellowship to undertake his postdoctoral training in Germany. During his postdoctoral training, Dr. Asif investigated the role of innate lymphoid cells (ILCs) and associated players in the progression of hepatocellular carcinoma.
In addition to his academic and medical responsibilities, Dr. Asif is heading a cancer research group where his team is actively investigating tumour microenvironment and potential markers of diagnostic, prognostic and therapeutic significance. Dr. Asif has also working to establish cancer registration in Pakistan.

Dr. Pravin Kesarwani

Molecular Genetic Radiation Oncology Research William Beaumont Research Institute, USA

pravin.kesarwani@gmail.com


DR. Kesarwani has been interested in tumor immunity, especially in cancer immunotherapy. One of his major project involved understanding how tumors utilize constant stimulation of antitumor T cells to induce cell death. They recently identified that T effector cell induces programmed necrosis of T cells. Inhabiting such unconventional form of cell death helps improve persistence of anti-tumor T cells and enhanced tumor control. They also found that antioxidants and cell surface thiols help increase T cell memory population. Moreover, they also found that mTOR inhibition has the results in increased cell surface thiols as well as antioxidant capacity, which gives them an edge over untreated effector T cells which have lower cell surface thiols and lower antioxidant capacity. He has also undertaken various other projects associated with understanding and increasing efficacy of immunotherapy.

Dr. Hamideh Salimzadeh

Health Promotion Assistant Professor, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

salimzadeh.h@gmail.com

Dr. Rahmatollah Moradzadeh

Epidemiology Assistant Professor Department of Epidemiology, School of Public Health, Arak University of Medical Sciences, Arak. Iran

moradzadehr@yahoo.com

Dr. Parastoo Hajian

Radiation Oncology Dept. of Radiotherapy, Medical School, Shahid Beheshti University of Medical Sciences, Department of radiation oncology, Shohad-e-Tajrish Hospital

parastoo.hajian@yahoo.com

Dr. Constance Lay Lay Saw

Pharmaceutical Sciences Center for Cancer Prevention Research Department of Pharmaceutics Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey, USA

constancesaw@gmail.com


Dr. Constance Saw is a Ph.D. in pharmaceutical sciences with post-doctoral training in drug delivery systems and chemoprevention. She has intensive research experience in the area of the pharmacodynamics of gene expression, signaling and metabolism of natural and synthetic cancer chemopreventive compounds/neutraceuticals in food and plant sources. After a few years of working as a pharmacist in National Cancer Centre Singapore (NCCS), Constance decided to make a conscious effort to shift her research and training focus to the bio-medical area and took up a Ph.D. course. Her wish was to work on basic research that could be translated into clinical practice to improve the treatment/quality of life of cancer patients.

Dr. Pratheeshkumar Poyil

Biotechnology Associate Scientist King Faisal Specialist Hospital & Research Center Riyadh, Saudi Arabia

ppratheeshkumar@gmail.com


Dr. Pratheeshkumar Poyil is an Associate Scientist at Human Cancer Genomics research, King Faisal Specialist Hospital and Research Centre (KFSH&RC) Riyadh, Saudi Arabia. Before joining at KFSH&RC, he was a Research Associate in the Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, USA for a period of 2011- 2016. He received his PhD degree in Tumor Immunology from Mahatma Gandhi University in 2011. He has been an author or co-author of more than 58 published research articles including reviews and book chapters; these articles have received 1448 citations with an H-index of 23 (Google Scholar, up to December 25, 2017). Add to this, he is an active reviewer of more than 20 international research journals. He is a member of editorial boards of International Journals and served as guest editor for 4 special journal issues in his research area. He is a highly motivated and innovative molecular biologist expertise in development and execution of translational biology, genetic and biochemistry-based research methods. His research interest includes the elucidation of cancer chemo-resistance mechanisms; identification of novel therapeutic targets in breast, papillary thyroid, colon and ovarian cancers and their targeting with small molecule inhibitors.

Dr. Ajaz Ahmad Bhat

Cancer Biology Interim Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar

abhat@sidra.org
0000-0003-3640-6275


Dr Bhat is currently working as a research scientist at Dept. of Translational Medicine, Sidra Medicine, Qatar. He completed his PhD from one of the premier institutes (All India Institute of Medical Sciences, AIIMS) in India. During Ph.D., he carried his reaserch on “Development of peptide based vaccine for Malraia, HIV and plague using immunoadjuvants and novel delivery vehicles”. After his Ph.D., he moved to Vanderbilt University Medical School, Nashville, TN, the USA for a postdoctoral fellowship.  During his eight years of postdoctoral training at Vanderbilt, he has gained broad experience in the field of cancer biology. His focus of the research was on the role and regulation of tight junction proteins (Claudins) in colorectal cancer and the role of bile acid-induced APE1/Ref1 in esophageal adenocarcinoma. He has published in well-reputed journals like Nature Communications, GUT, Oncogene, Cancer Research, Molecular Cancer and many more enlisted in his CV. He has attended many international meetings, conferences, symposia to present his research results. He has been awarded from Immunology society and American Association of Cancer research. He has also been awarded as an outstanding researcher for the year 2018 and 2019 from Sidra Medicine. He is an active member of many immunological and cancer societies. He is also serving in the editorial board and review committee of many journals.